Portuguese 
English 
Spanish 
5 min of reading 
0 comments 
Swiss prototype uses glucose present in the body to generate energy in bioelectronic devices, but the technology is still in an experimental phase and depends on new tests before reaching patients.
Researchers at ETH Zurich, in Switzerland, have developed an implantable fuel cell capable of generating electricity from glucose, the sugar that circulates in the body after eating.
The technology is still in the prototype phase and has been tested on mice, according to the Swiss university.
The system was presented as an experimental alternative to power low-power bioelectronic devices.
-
The strongest El Niño in the last 10 years will hit Santa Catarina, and the meteorologist who issued the warning said that it’s not alarmism, it’s reality, and needs to be treated seriously.
-
Ibama is using drones, remote sensing, and artificial intelligence to hunt an Asian invasive plant in the mangroves of Cubatão before it spreads along the Brazilian coast, and more than 700 trees of the species have already been manually removed.
-
Giant octopuses up to 19 meters dominated the oceans 100 million years ago, and new 3D technology reveals what the true apex predators of the sea were like.
-
Brazil will face a week of climatic extremes with temperatures ranging from 0 degree in Serra Gaúcha to 36 degrees in the Southeast, rainfall of up to 200 millimeters in the North and Northeast, and a polar air mass that promises to be the most intense of 2026.
The proposal, however, does not yet correspond to a battery ready for human use, nor does it currently replace the batteries used in pacemakers, insulin pumps, or other medical implants.
Fuel cell uses glucose to generate energy
The fuel cell created by the team led by Martin Fussenegger, professor of biotechnology and bioengineering at ETH Zurich, uses excess glucose present in tissues to produce electrical energy.
The principle is similar to that of a fuel cell, but adapted to the biological environment.
At the center of the device is an anode made with copper-based nanoparticles.
This component divides glucose into gluconic acid and protons, a process that releases electrons and allows the formation of an electric current.
The university states that the prototype is encased in a non-woven fabric and coated with alginate, an algae-derived substance used in medical applications.
This coating allows the entry of bodily fluids and, with them, the glucose necessary for the reaction.
Due to its shape, ETH Zurich compares the device to a small tea bag, slightly larger than a fingernail.
The description helps to size the prototype, but does not indicate that it is ready for clinical implantation in patients.
Difference between common battery and Swiss prototype
Traditional batteries store a limited amount of chemical energy.
In implantable medical devices, charge loss may require recharges, technical monitoring, or replacement procedures, depending on the type of equipment.
The Swiss fuel cell operates on a different logic.
Instead of relying on a pre-stored charge, it uses a molecule already present in the body.
When there is excess glucose, the system generates electricity; when the level drops below a certain threshold, energy production is stopped.
According to Fussenegger, the consumption of carbohydrates above the daily need in part of the population motivated the idea of using excess metabolic energy to power biomedical devices.
The statement was released in an official communication from ETH Zurich.
This mechanism was presented, above all, in the context of research on type 1 diabetes.
In the experiment, scientists combined the fuel cell with artificial beta cells, designed to release insulin when stimulated by electric current or blue light.
In tests with diabetic mice, the assembly allowed for the stimulation of insulin production and release when there was an increase in glucose.
After the reduction of blood sugar, the generation of energy and the release of insulin were stopped.
Possible uses in medical implants
ETH Zurich states that the technology could be used, in the future, to operate medical devices.
The university cites applications that depend on a reliable energy supply, such as insulin pumps and pacemakers, but treats this possibility as a future step.
So far, there is no confirmation of human use.
There is also no public demonstration that the system can power, under real clinical conditions, a pacemaker, a commercial insulin pump, or implantable continuous monitoring sensors.
The more precise formulation, therefore, is that researchers have developed a prototype capable of generating energy from glucose in an experimental model.
Application in commercial medical implants would depend on further testing, safety evaluation, and regulatory validation.
There is also no solid basis to state that the fuel cell would function for decades inside the human body.
The study indicates an energy source associated with glucose availability, but does not prove prolonged durability in patients.
Chemical safety and device limits
The reaction described by the researchers converts glucose into gluconic acid and protons, with the release of electrons into the circuit.
Therefore, it is not correct to state, based on the available sources, that the system produces only water as waste.
The alginate coating and encapsulated structure were designed to favor controlled contact with body fluids.
Even so, the released data do not allow concluding that the device has already demonstrated absence of inflammation, rejection, or adverse effects in humans.
Another limit lies in the purpose of the experiment.
The fuel cell was integrated into an insulin control system, not presented as a universal battery for any type of implant.
The energy generated depends on metabolic conditions and the electrical demand of the connected device.
In a report from the medical technology sector, MedTech Dive highlighted that the cell produced energy during hyperglycemia and also allowed communication with external devices, such as smartphones, in the context of the experimental system.
This information reinforces the potential for connectivity, but does not equate to clinical approval.
What is missing to reach patients
ETH Zurich reports that the technology remains a prototype and it is not yet clear whether it will reach the market.
The university itself points out that transforming the research into a product would require financial resources, specialized staff, and industrial partnerships.
For implantable devices, the transition between laboratory and medical use requires more than just technical functionality.
It is necessary to demonstrate stability, biocompatibility, risk control, and clinical benefit compared to already available alternatives.
The research brings together bioelectronics, metabolic engineering, and cell therapy in the same experimental system.
This type of integration allows investigating ways to use the body’s own molecules as an energy source for low-power medical devices.
At the current stage, the Swiss advance shows that glucose can power implantable circuits under controlled research conditions.
Adapting this strategy for implants used in patients still depends on proof of safety and efficacy.
Be the first to react!